Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Dow
Express Scripts
McKesson
Moodys

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Quizartinib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Quizartinib?

Quizartinib is an investigational drug.

There have been 24 clinical trials for Quizartinib. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2014.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Daiichi Sankyo Inc., National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are twenty-two US patents protecting this investigational drug and one hundred and eighty-eight international patents.

Recent Clinical Trials for Quizartinib
TitleSponsorPhase
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeNational Cancer Institute (NCI)Phase 1/Phase 2
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeM.D. Anderson Cancer CenterPhase 1/Phase 2
A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid LeukemiaSCRI Development Innovations, LLCPhase 2

See all Quizartinib clinical trials

Clinical Trial Summary for Quizartinib

Top disease conditions for Quizartinib
Top clinical trial sponsors for Quizartinib

See all Quizartinib clinical trials

US Patents for Quizartinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Quizartinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Quizartinib   Start Trial Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Quizartinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Quizartinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Quizartinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Quizartinib

Drugname Country Document Number Estimated Expiration Related US Patent
Quizartinib Argentina 109919 2036-10-10   Start Trial
Quizartinib Australia 2017342022 2036-10-10   Start Trial
Quizartinib Brazil 112019007144 2036-10-10   Start Trial
Quizartinib Canada 3039760 2036-10-10   Start Trial
Quizartinib China 110382494 2036-10-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
McKinsey
Johnson and Johnson
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.